ArticleMedicine and science in sports and exercise2026
Residence at 1200 m Induces a Threefold Reduction in the Risk of Acute Mountain Sickness After Rapid Ascent to 3600 m.
Article in Medicine and science in sports and exercise, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Moderate-altitude residence (1600-2400 m) elicits altitude acclimatization and reduces acute mountain sickness (AMS) after rapid ascent to higher altitude (HA). Cross-sectional studies suggest lower-altitude residence (800-1200 m) provides similar benefits, but conclusions are unclear due to a lack of control. PURPOSE: Determine whether moderate-altitude residents (MAR, 1200 m) experience less AMS than low-altitude residents (LAR) after active or passive ascent to HA (3600 m).
methodsSeventy-eight soldiers (mean ± standard deviation; age = 26 ± 5 yr; women = 8) were tested at their baseline residence at 331 m (LAR; n = 41) or 1200 m (MAR; n = 37), transported to Taos, NM (2845 m), hiked ( n = 39) or were driven ( n = 39) to 3600 m and stayed for 4 d. AMS was assessed using the Environmental Symptoms Questionnaire twice on day 1 (HA1), five times on days 2 and 3 (HA2, HA3), and once on day 4 (HA4). Daily peak cerebral factor score (AMS-C) was recorded; if AMS-C was ≥0.7, individuals were considered sick that day.
resultsAscent condition (active vs passive) did not demonstrate a significant main or interaction effect on AMS. The MAR versus LAR experienced lower AMS incidence on HA1 (16% vs 44%, P = 0.008) and HA2 (19% vs 39%, P = 0.05), similar incidence on HA3 (14% vs 29%, P = 0.08), and lower incidence on HA4 (0% vs. 17%, P = 0.007). AMS-C was lower in MAR versus LAR on HA1 (0.40 ± 0.49 vs 0.74 ± 0.86, P = 0.04), HA2 (0.30 ± 0.34 vs 0.86 ± 0.88, P = 0.001), HA3 (0.30 ± 0.36 vs 0.56 ± 0.69, P = 0.03), and HA4 (0.09 ± 0.14 vs 0.35 ± 0.58, P = 0.01). MAR exhibited an approximately threefold reduction in the odds of developing AMS at HA1 (odds ratio [OR] = 0.25, P = 0.01), HA2 (OR = 0.37, P = 0.05), and HA3 (OR = 0.38, P = 0.09) compared with LAR.
conclusionsResidence at 1200 m induces a threefold reduction in the odds of developing AMS after rapid ascent to 3600 m.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.